Skip to main content
PMC home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1990 Jun;87(11):4058–4062. doi: 10.1073/pnas.87.11.4058

Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines.

B S Packard 1
PMCID: PMC54046  PMID: 2190213

Abstract

Tumor-infiltrating lymphocytes (TILs) have shown in vivo antitumor efficacy in both animal and human studies. Functions thought necessary for antitumor activity include cytolysis, homing, and proliferation at tumor sites. TILs, which are T lymphocytes grown ex vivo directly from tumors, bear interleukin 2 (IL-2) receptors capable of transducing the IL-2 mitogenic signal. However, IL-2 is not normally synthesized by solid tumor cells. This study was aimed at exploring the possible presence of T-cell mitogens of tumor origin. To this end four TIL lines derived from four melanoma patients were studied for their ability to use the environments of cultured tumor cell lines as mitogenic sources. The presence of four irradiated cultured human tumor cell lines, three of which were derived from the same melanoma patients as the TILs, were found to stimulate proliferation of human TILs in the absence of IL-2. Further investigation showed that the observed proliferative stimulation by the fourth tumor line was due to secreted factor(s) as mitogenic activity was present in the serum-free tumor cell supernatant. Both immunologic analyses of this medium and proliferative assays in which TILs were stimulated with recombinant lymphokine standards suggest the presence of a yet uncharacterized T-cell mitogen.

Full text

PDF
4058

Images in this article

4059Image
on p.4059
4059Image
on p.4059
4060Image
on p.4060
4061Image
on p.4061

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Itoh K., Tilden A. B., Balch C. M. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res. 1986 Jun;46(6):3011–3017. [PubMed] [Google Scholar]
  2. Kirnbauer R., Köck A., Schwarz T., Urbanski A., Krutmann J., Borth W., Damm D., Shipley G., Ansel J. C., Luger T. A. IFN-beta 2, B cell differentiation factor 2, or hybridoma growth factor (IL-6) is expressed and released by human epidermal cells and epidermoid carcinoma cell lines. J Immunol. 1989 Mar 15;142(6):1922–1928. [PubMed] [Google Scholar]
  3. Kradin R. L., Boyle L. A., Preffer F. I., Callahan R. J., Barlai-Kovach M., Strauss H. W., Dubinett S., Kurnick J. T. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother. 1987;24(1):76–85. doi: 10.1007/BF00199837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lee S. K., Oliver R. T. Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia. J Exp Med. 1978 Mar 1;147(3):912–922. doi: 10.1084/jem.147.3.912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Miescher S., Whiteside T. L., Moretta L., von Fliedner V. Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol. 1987 Jun 1;138(11):4004–4011. [PubMed] [Google Scholar]
  6. Mitsuya H., Matis L. A., Megson M., Bunn P. A., Murray C., Mann D. L., Gallo R. C., Broder S. Generation of an HLA-restricted cytotoxic T cell line reactive against cultured tumor cells from a patient infected with human T cell leukemia/lymphoma virus. J Exp Med. 1983 Sep 1;158(3):994–999. doi: 10.1084/jem.158.3.994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Packard B. S. Identification of a synthetic nonapeptide sequence that inhibits motility in culture of a melanoma subclone that possesses a high metastatic potential. Proc Natl Acad Sci U S A. 1987 Dec;84(24):9015–9019. doi: 10.1073/pnas.84.24.9015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Rabinowich H., Cohen R., Bruderman I., Steiner Z., Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 1987 Jan 1;47(1):173–177. [PubMed] [Google Scholar]
  9. Rosenberg S. A., Packard B. S., Aebersold P. M., Solomon D., Topalian S. L., Toy S. T., Simon P., Lotze M. T., Yang J. C., Seipp C. A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988 Dec 22;319(25):1676–1680. doi: 10.1056/NEJM198812223192527. [DOI] [PubMed] [Google Scholar]
  10. Rosenberg S. A., Spiess P., Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986 Sep 19;233(4770):1318–1321. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  11. Slovin S. F., Lackman R. D., Ferrone S., Kiely P. E., Mastrangelo M. J. Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol. 1986 Nov 1;137(9):3042–3048. [PubMed] [Google Scholar]
  12. Smith K. A. Interleukin-2: inception, impact, and implications. Science. 1988 May 27;240(4856):1169–1176. doi: 10.1126/science.3131876. [DOI] [PubMed] [Google Scholar]
  13. Smith K. A. The interleukin 2 receptor. Adv Immunol. 1988;42:165–179. doi: 10.1016/s0065-2776(08)60844-5. [DOI] [PubMed] [Google Scholar]
  14. Topalian S. L., Muul L. M., Solomon D., Rosenberg S. A. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods. 1987 Aug 24;102(1):127–141. doi: 10.1016/s0022-1759(87)80018-2. [DOI] [PubMed] [Google Scholar]
  15. Treves A. J., Cohen I. R., Feldman M. Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro. J Natl Cancer Inst. 1975 Mar;54(3):777–780. [PubMed] [Google Scholar]
  16. Vose B. M., Bonnard G. D. Human tumour antigens defined by cytotoxicity and proliferative responses of cultured lymphoid cells. Nature. 1982 Mar 25;296(5855):359–361. doi: 10.1038/296359a0. [DOI] [PubMed] [Google Scholar]
  17. Vose B. M., Bonnard G. D. Specific cytotoxicity against autologous tumour and proliferative responses of human lymphocytes grown in interleukin 2. Int J Cancer. 1982 Jan 15;29(1):33–39. doi: 10.1002/ijc.2910290107. [DOI] [PubMed] [Google Scholar]
  18. Vánky F., Gorsky T., Gorsky Y., Masucci M. G., Klein E. Lysis of tumor biopsy cells by autologous T lymphocytes activated in mixed cultures and propagated with T cell growth factor. J Exp Med. 1982 Jan 1;155(1):83–95. doi: 10.1084/jem.155.1.83. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Zarling J. M., Bach F. H. Continuous culture of T cells cytotoxic for autologous human leukaemia cells. Nature. 1979 Aug 23;280(5724):685–688. doi: 10.1038/280685a0. [DOI] [PubMed] [Google Scholar]
  20. de Vries J. E., Spits H. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity. J Immunol. 1984 Jan;132(1):510–519. [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES